|
|
 |
|
Viewing report
|
|
|
|
Astellas Pharma Inc. (4503) - Financial and Strategic SWOT Analysis Review
GlobalData, March 2012, Pages: 48
Astellas Pharma Inc. (4503) - Financial and Strategic SWOT Analysis Review
Summary
Astellas Pharma Inc. (Astellas) is one of JPYthe leading global pharmaceutical companies engaged in research, development, manufacturing and commercialization pharmaceuticals. The company operates in a single reportable business segment, pharmaceuticals. Astellas’s product portfolio comprises both marketed as well as pipeline products targeted against a wide range of diseases related to fields such as urology, transplantation, immunology, infectious diseases, oncology, neuroscience, and metabolic diseases among others. The company has its operations spread across 40 countries worldwide divided into four key geographies, namely, Japan, Americas, Europe, and Asia and Oceania through its network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.
The company focuses on successful development of its existing product pipeline as well as discovery of newer compounds targeted on unmet pharmaceutical needs of the people spread across various therapeutic fields. This can be supported by the various recent research and development agreements signed by the company with Sanwa Kagaku Kenkyusho Co. Ltd., RIKEN, . The company also focuses on its commitment towards creation of a strong brand which can be reflected from the recent launch of television commercial with a slogan of ‘Changing Tommorrow’. In addition, the company also concentrates on fulfilling its corporate social responsibilities through small efforts as reflected from the recently received awards by Ireland Japan Chamber of Commerce and inclusion in the Dow Jones sustainability Asia-Pacific index.
Astellas Pharma Inc. Key Recent Developments
Feb 29, 2012: Sanofi And Astellas To Dissolve Sanofi-Aventis Yamanouchi Pharmaceutical
Feb 21, 2012: Astellas Hires Charlotte Kremer As Senior Vice President Of New Global Medical Affairs Organization
Feb 01, 2012: Astellas Pharma Reports Net Sales Of JPY763.9 Billion For Nine Months Ended December 31, 2011
Nov 01, 2011: Astellas Pharma Reports Net Sales Of JPY483.9 Billion In H1 Fiscal 2011
Aug 01, 2011: Astellas Reports Net Sales Of JPY251.6 Billion For Q1 Fiscal 2011
This comprehensive SWOT profile of Astellas Pharma Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Key Words
Astellas Pharma Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Customers who bought this item also bought
Astellas Pharma Inc. - Strategy and SWOT Report
Ono Pharmaceutical Co., Ltd. (4528) - Financial and Strategic SWOT Analysis Review
Mitsubishi Tanabe Pharma Corporation (4508) - Financial and Strategic SWOT Analysis Review
Sanofi (SAN) - Financial and Strategic SWOT Analysis Review
GlaxoSmithKline plc (GSK) - Financial and Strategic SWOT Analysis Review
Astellas Pharma Inc. - Product Pipeline Review - H2 2011
ViroPharma Incorporated (VPHM) - Financial and Strategic SWOT Analysis Review
OSI Pharmaceuticals, Inc. - Financial and Strategic SWOT Analysis Review
Shionogi & Co., Ltd. (4507) - Financial and Strategic SWOT Analysis Review
Aptalis Pharma Inc. - Strategic SWOT Analysis Review
|
|
|
|
